Suppr超能文献

溴己新(“必嗽平”)治疗慢性支气管炎门诊患者的对照试验。

A controlled trial of bromhexine ('Bisolvon') in out-patients with chronic bronchitis.

作者信息

Lal S, Bhalla K K

出版信息

Curr Med Res Opin. 1975;3(2):63-7. doi: 10.1185/03007997509113648.

Abstract

Bromhexine, 16 mg. 3-times daily, was compared with placebo in a double-blind crossover trial in 41 out-patients with chronic bronchitis and irreversible airways obstruction, and who were considered to be in a steady state. Each treatment was given for 3 weeks with a week of placebo in between; in addition, all patients took oxytetracycline, 500 mg. twice daily, starting 1 week before the trial and continuing throughout the duration of it. All patients completed the trial but the results from 5 were excluded because during the first 3 weeks they developed an influenza-like illness accompanied by a decrease in FEV1,and peak expiratory flow rate. Results from the remaining 36 patients showed a statistically significant reduction in phlegm stickiness (p smaller than 0.05) as judged by the patient, and a significant improvement in overall clinical state (p smaller than 0.05) as judged by the physician during bromhexine treatment, but no significant change in symptoms like cough, chest tightness, ease of breathing or sputum volume, peak expiratory flow rate and FEV1 etc. Five patients reported 6 side-effects, 3 with bromhexine, 1 with placebo and 1 with both treatments.

摘要

在一项双盲交叉试验中,对41例患有慢性支气管炎且存在不可逆气道阻塞、被认为处于稳定状态的门诊患者,将16毫克溴己新每日3次的治疗方案与安慰剂进行了比较。每种治疗持续3周,中间间隔1周的安慰剂治疗;此外,所有患者从试验前1周开始每日2次服用500毫克土霉素,并在试验期间持续服用。所有患者均完成了试验,但有5例患者的结果被排除,因为在最初3周内他们患上了类似流感的疾病,同时第一秒用力呼气量(FEV1)和呼气峰值流速下降。其余36例患者的结果显示,在溴己新治疗期间,患者判断痰液黏稠度有统计学意义的降低(p小于0.05),医生判断总体临床状态有显著改善(p小于0.05),但咳嗽、胸闷、呼吸 ease of breathing(原文有误,推测为ease of breath)、痰量、呼气峰值流速和FEV1等症状无显著变化。5例患者报告了6例副作用,3例与溴己新有关,1例与安慰剂有关,1例与两种治疗均有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验